Senores
Committed to Global Wellness!

Date: July 27, 2026

To, Sr. General Manager Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 **BSE Scrip Code: 544319**	To, Sr. General Manager Listing Department **National Stock Exchange of India Limited** Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051 **NSE Symbol: SENORES**

Sub.: Submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible equity warrants, for the quarter ended on June 30, 2026

Dear Sir/Madam,

Pursuant to Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 and SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, please find enclosed herewith the statement of deviation(s) or variation(s) in utilisation of funds raised through preferential issue of 11,70,000 convertible equity warrants by the Company, for the quarter ended June 30, 2026.

We hereby confirm that there has been no deviation(s) or variation(s) in the utilization of the funds raised through preferential issue of convertible equity warrants, for the abovementioned period, for the objects stated in the explanatory statement to the Notice of the Extra-ordinary General Meeting held on January 31, 2026.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on July 27, 2026.

This intimation is also being uploaded on the website of the Company i.e., www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

DEVAL RAJNIKANT SHAH
Digitally signed by DEVAL RAJNIKANT SHAH
Date: 2026.07.27 17:43:47 +05'30'

Deval Rajnikant Shah
Whole Time Director & CFO
DIN: 00332722

Enclosure: As above

Senores
Committed to Global Wellness!

STATEMENT OF DEVIATION(S) / VARIATION(S) IN UTILISATION OF FUNDS RAISED THROUGH IPO, FOR THE QUARTER ENDED JUNE 30, 2026

Name of listed entity	Senores Pharmaceuticals Limited
Mode of Fund Raising	Preferential Issue of 11,70,000 Convertible Equity Warrants each convertible into one Equity Share of face value ₹10/- (Rupees Ten only) each, at an exercise price of ₹ 812/- (Rupees Eight Hundred and Twelve only) per Warrant
Date of Raising Funds	March 28, 2026
Amount Raised	Rs. 95,00,40,000
Report filed for Quarter ended	June 30, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No comments
Comments of the auditors, if any	No comments

Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	**Modified Object, if any**	**Original Allocation**	**Modified Allocation, if any**	**Funds Utilized**	**Amount of Deviation/ Variation for the quarter according to applicable object**	**Remarks, if any**
Funding the working capital requirements of our Company	Not Applicable	31,25,30,000	Not Applicable	6,84,00,000	No deviation	-

Funding the product development expenditure for the Company	Not Applicable	25,00,00,000	Not Applicable	Nil	No deviation	-
Investment in our subsidiaries, by way of loan, to fund their working capital requirements	Not Applicable	15,00,00,000	Not Applicable	6,15,01,000	No deviation	-
General Corporate Purpose	Not Applicable	23,75,10,000	Not Applicable	3,92,09,000	No deviation	-
Total		**95,00,40,000**		**16,91,10,000**		

Deviation or variation could mean:
(a) Deviation in the objects or purposes for which the funds have been raised; or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
(c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc

For Senores Pharmaceuticals Limited

DEVAL RAJNIKANT SHAH

Digitally signed by DEVAL RAJNIKANT SHAH
Date: 2026.07.27 17:44:14 +05'30'

Deval Rajnikant Shah
Whole Time Director & CFO
DIN: 00332722